An IgA-oriented bifidobacterial composition for mucosal immune support: Formulation design, postbiotic synergy, and evidence context
Clara Braun
European Life Science Research Association
Anas Ziraoui
European Life Science Research Association
Charlotte Blanchard
European Life Science Research Association
DOI: https://doi.org/10.59429/pest.v8i2.14487
Keywords: BALIMONT; IgA; mucosal immunity; bifidobacterium; postbiotic; prebiotic; microencapsulation
Abstract
We examined a disclosed BALIMONT probiotic composition built around a live three-strain core, a heat-inactivated postbiotic fraction, prebiotic substrates, and a double-layer protective system. The retained dataset points to a coherent IgA-oriented design logic. In the screening phase, the equal-ratio live-strain group (2:2:2) produced the strongest secretory IgA signal and the highest proliferation index among the tested combinations. In the postbiotic-loading screen, a 1:1 ratio between heat-inactivated Lactococcus lactis and the live probiotic core provided the best balance between secretory IgA output and short-term viable-count retention. In the 28-day murine study, medium- and high-dose groups showed higher serum IgA, intestinal mucosal sIgA, and fecal sIgA than the blank and low-dose groups. Storage results further indicated meaningful viability preservation under standard and accelerated conditions. Public studies on bifidobacteria, encapsulation, prebiotic support, and non-live microbial preparations provide a compatible evidence backdrop for the disclosed formulation strategy. Taken together, the composition can be read as a technically integrated mucosal-immune-support platform whose distinctiveness lies in the coordination of strain balance, postbiotic synergy, and delivery engineering.
References
[1] Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014, 11(8): 506-514. PMID: 24912386.
[2] Salminen S, Collado MC, Endo A, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021,18(9): 649-667. PMID: 33948025. doi:10.1038/s41575-021-00440-6.
[3] Gibson GR, Hutkins R, Sanders ME, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017, 14(8): 491-502. PMID: 28611480. doi:10.1038/nrgastro.2017.75.
[4] Takahashi T, Ohta N, Miyaoka Y. Effects of orally ingested Bifidobacterium longum on the mucosal IgA response of mice to dietary antigens. Biosci Biotechnol Biochem. 1998, 62(1): 10-15. PMID: 9501512. doi:10.1271/bbb.62.10.
[5] Park JH, Um JI, Lee BJ, et al. Encapsulated Bifidobacterium bifidum potentiates intestinal IgA production. Cell Immunol. 2002, 219(1): 22-27. PMID: 12473264. doi:10.1016/S0008-8749(02)00579-8.
[6] Tanaka K, Fujiwara T, Nagana Gowda GA, et al. Bifidobacterium bifidum OLB6378 simultaneously enhances systemic and mucosal humoral immunity in low birth weight infants: a non-randomized study. Nutrients. 2017, 9(3): 195. PMID: 28245626. doi:10.3390/nu9030195.
[7] Terahara M, Nakamura S, Kyoui D, et al. Effects of the intake of non-live Bifidobacterium bifidum on the faecal IgA of full-term infants: a double-blind, randomised, placebo-controlled study. Biosci Microbiota Food Health. 2021, 40(4): 196-203. PMID: 34631331. doi:10.12938/bmfh.2021-018.